The stock of ITeos Therapeutics Inc (ITOS) has gone up by 0.11% for the week, with a 17.19% rise in the past month and a 53.97% rise in the past quarter. The volatility ratio for the week is 0.89%, and the volatility levels for the past 30 days are 3.77% for ITOS. The simple moving average for the past 20 days is -0.34% for ITOS’s stock, with a 19.72% simple moving average for the past 200 days.
Is It Worth Investing in ITeos Therapeutics Inc (NASDAQ: ITOS) Right Now?
Additionally, the 36-month beta value for ITOS is 1.51. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 1 rating it as “overweight,” 5 rating it as “hold,” and 0 rating it as “sell.”
The public float for ITOS is 35.88M and currently, short sellers hold a 7.06% ratio of that float. The average trading volume of ITOS on June 25, 2025 was 1.29M shares.
ITOS) stock’s latest price update
ITeos Therapeutics Inc (NASDAQ: ITOS)’s stock price has plunge by -0.58relation to previous closing price of 10.09. Nevertheless, the company has seen a 0.11% surge in its stock price over the last five trading sessions. zacks.com reported 2025-05-30 that iTeos Therapeutics (ITOS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company’s earnings prospects. This might drive the stock higher in the near term.
Analysts’ Opinion of ITOS
Many brokerage firms have already submitted their reports for ITOS stocks, with Wells Fargo repeating the rating for ITOS by listing it as a “Equal Weight.” The predicted price for ITOS in the upcoming period, according to Wells Fargo is $12 based on the research report published on May 28, 2025 of the current year 2025.
Wedbush, on the other hand, stated in their research note that they expect to see ITOS reach a price target of $12. The rating they have provided for ITOS stocks is “Neutral” according to the report published on May 28th, 2025.
Leerink Partners gave a rating of “Market Perform” to ITOS, setting the target price at $9 in the report published on May 14th of the current year.
ITOS Trading at 19.28% from the 50-Day Moving Average
After a stumble in the market that brought ITOS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -44.67% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ITOS starting from Detheux Michel, who sale 43,882 shares at the price of $10.03 back on Jun 09 ’25. After this action, Detheux Michel now owns 0 shares of ITeos Therapeutics Inc, valued at $440,136 using the latest closing price.
Detheux Michel, the Chief Executive Officer of ITeos Therapeutics Inc, sale 43,883 shares at $10.02 during a trade that took place back on Jun 10 ’25, which means that Detheux Michel is holding 0 shares at $439,708 based on the most recent closing price.
Stock Fundamentals for ITOS
Current profitability levels for the company are sitting at:
- -4.35 for the present operating margin
- 0.99 for the gross margin
The net margin for ITeos Therapeutics Inc stands at -3.74. The total capital return value is set at -0.25. Equity return is now at value -23.68, with -20.30 for asset returns.
Based on ITeos Therapeutics Inc (ITOS), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -19.7.
Currently, EBITDA for the company is -159.53 million with net debt to EBITDA at 1.02. When we switch over and look at the enterprise to sales, we see a ratio of 6.64. The receivables turnover for the company is 10.7for trailing twelve months and the total asset turnover is 0.05. The liquidity ratio also appears to be rather interesting for investors as it stands at 14.13.
Conclusion
In conclusion, ITeos Therapeutics Inc (ITOS) has seen better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
